Inhibitory effects of Lactobocillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats

Gut

Volumn 55, Issue 2, 2006, Pages 191-196

  Kamiya, T ^b   Wang, L ^b   Forsythe, P ^b   Goettsche, G ^b   Mao, Y ^b   Wang, Y ^b   Tougas, G ^b   Bienenstock, J ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT;

ABDOMINAL DISTENSION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIUM CULTURE; COLORECTAL DISEASE; CONTROLLED STUDY; CULTURE MEDIUM; ELECTROCARDIOGRAPHY; HEART RATE; INTESTINE INNERVATION; LACTOBACILLUS REUTERI; MALE; NONHUMAN; PAIN ASSESSMENT; PAW PRESSURE TEST; PRIORITY JOURNAL; RAT; SPINAL GANGLION; TAIL FLICK TEST; THERMAL STIMULATION; TREATMENT OUTCOME; VISCERAL PAIN; ANIMAL; BALLOON DILATATION; FECES; ISOLATION AND PURIFICATION; LARGE INTESTINE; METHODOLOGY; MICROBIOLOGY; PAIN; PAIN THRESHOLD; PATHOPHYSIOLOGY; PRESSURE; SPRAGUE DAWLEY RAT; STIMULATION;

ANIMALS; BALLOON DILATATION; CULTURE MEDIA, CONDITIONED; FECES; GANGLIA, SPINAL; HEART RATE; INTESTINE, LARGE; LACTOBACILLUS REUTERI; MALE; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; PHYSICAL STIMULATION; PRESSURE; PROBIOTICS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 30944450776     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.070987     Document Type: Article

References (49)

1. Fuller R. Probiotics in human medicine. Gut 1991;32:439-42.
2. Cremonini F, Di Caro S, Nista EC. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhea. Aliment Pharmacol Ther 2002;16:1461-7.
3. D'Souza AL, Rajkumar C, Cooke J. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002;324:1361-5.
4. Wullt M, Hagslatt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhea: a double-blind, placebo-controlled trial. Scand J Infect Dis 2002;186:1781-9.
5. Szajewska H, Mrukowicz JZ. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr 2001;33(suppl 2):S17-S25.
6. Rosenfeldt V, Michaelsen KF, Jakobsen M. Effect of probiotic Lactobacillus strains in young children hospitalized with acute diarrhea. Pediatr Infect Dis J 2002;21:411-16.
7. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999;13:1103-8.
8. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Eschrichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet 1999;354:635-9.
9. Barruel N, Caral M, Casellas, et al. Increased mucosal tumor necrosis factor a production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 2002;51:659-64.
10. Laake KO, Line PD, Aabakken L, et al. Assessment of mucosal inflammation and circulation in response to probiotics in patients operated with ileal pouch anal anastomosis for ulcerative colitis. Scand J Gastroenterol 2003;38:409-14.
11. Gionchetti P, Rizzello F, Hekvig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial. Gastroenterology 2003;124:1202-9.
12. Kalliomaki M, Salminen S, Arviommi H, et al. Probiotics in primary prevention of atopic disease: a randomized placebo controlled trial. Lancet 2001;357:1076-9.
13. McCarthy J, O'Mahony L, Callaghan LO, et al. Double blind placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003;52:975-80.
14. Madsen KL, Doyle JS, Jewell LD, et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999;116:1107-14.
15. Rachmilewitz D, Katakura K, Karmeli F, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004;126:520-8.
16. Fujiwara M, Kaneko T, Iwata H, et al. Inhibitory effects of Bifidobacterium longum on experimental ulcerative colitis induced in mice by synthetic dextran sulfate sodium. Digest 2003;67:90-5.
17. Dieleman LA, Goerres MS, Arends A, et al. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 2003;52:370-6.
18. Drossman DA, Corazziari E, Talley NJ, et al. Rome II: A multinational consensus document on functional gastrointestinal disorders. Gut 1999;45(Suppl 2):1-81.
19. Mertz H, Naliboff B, Munakata J, et al. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995;109:40-52.
20. Schmulson M, Chang L, Naliboff B, et al. Correlation of symptom criteria with perception thresholds during rectosigmoid distension in irritable bowel syndrome patients. Am J Gastroenterol 2000;95:152-6.
21. Delvaux M. Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. Gut 2002;51(Suppl 1):i67-i71.
22. Tougas G. The autonomic nervous system in functional bowel disorders. Gut 2000;47(Suppl 4):78-80.
23. Ness TJ, Gebhart GF. Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudoaffective reflexes in the rat. Brain Res 1988;450:153-69.
24. Kamp EH, Jones RCWI, Tillman SR, et al. Quantitative assessment and characterization of visceral nociception and hyperalgesia in mice. Am J Physiol 2003;284:G434-G444.
25. Nobaek S, Johansson ML, Molin G, et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:1231-8.
26. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001;13:1143-7.
27. Kim HJ, Camilleri M, Mckinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003;17:895-904.
28. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-51.
29. Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 2005;115:5-9.
30. Tougas G, Wang L. Pseudoaffective cardioautonomic responses to gastric distension in rats. Am J Physiol 1999;277:R272-R278.
31. Bercik P, Wang L, Verdu E, et al. Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction. Gastroenterology 2004;127:179-87.
32. Bardin L, Bardin M, Lavarenne J, et al. Effect of intrathecal serotonin on nociception in rats: influence of the pain test used. Exp Brain Res 1997;113:81-7.
33. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004;126:1620-33.
34. Shanahan F. Therapeutic manipulation of gut flora. Science 2000;289:1311-12.
35. Ma D, Wolvers D, Stanisz AM, et al. Interleukin-10 and nerve growth factor have reciprocal upregulatory effects on intestinal epithelial cells. Am J Physiol Regul Integr Comp Physiol 2003;284:R1323-R1329.
36. Schultz M, Sartor RB. Probiotics and inflammatory bowel diseases. Am J Gastroenterol 2000;95(Suppl):S19-S21.
37. Ma D, Forsythe P, Bienenstock J. Live Lactobacillus reuteri is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression. Infect Immun 2004;72:5308-14.
38. Aggarwal A, Cutts TF, Abell TL, et al. Predominant symptoms in irritable bowel syndrome correlate with specific autonomic nervous system abnormalities. Gastroenterology 1994;106:945-50.
39. Kamm K, Hoppe S, Breves G, et al. Effects of the probiotic yeast Saccharomyces boulardii on the neurochemistry of myenteric neurones in pig jejunum. Neurogastroenterol Mot 2004;16:53-60.
40. Lamine F, Eutamene H, Fioramonti J, et al. Colonc responses to Lactobacillus farciminis treatment in trinitrobenzene sulphonic acid-induced colitis in rats. Scand J Gastroenterol 2004;39:1250-8.
41. Husebye E, Hellstrom PM, Sundler F, et al. Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats. Am J Physiol Gastrointest Liver Physiol 2001;280:G368-G380.
42. Chauviere G, Coconnier MM, Kerneis S, et al. Competitive exclusion of diarrheagenic Escherichia coli (ETEC) from human enterocyte-lilce Caco-2 cells by heat-killed Lactobacillus. FEMS Microbiol Lett 1992;70:213-17.
43. Grangette C, Nutten S, Palumbo E, et al. Enhanced antiinflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids. Proc Natl Acad Sci U S A 2005;102:10321-6.
44. Modlin RL. A Toll for DMA vaccines. Nature 2000;408:659-660.
45. Chu W, Gong X, Li Z. DNA-PKcs is required for activation of innate immunity by immunostimulatory DNA. Cell 2000;103:909-18.
46. Jijon H, Backer J, Diaz H, et al. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 2004;126:1358-73.
47. Ho B, Wang L, Tougas G. The neurocardiac response to colonic distension is mediated through sympathovagal neural pathways in rats. Gastroenterology 1996;110:A679.
48. Verdu EF, Bercik P, Bergonzelli GE, et al. Lactobocillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction. Gastroenterology 2004;127:826-37.
49. Verdu E, Bercik P, Verma-Gandhu M, et al. Specific probiotic therapy attenuates antibiotic-induced visceral hypersensitivity in mice. Gut 2005,doi:10.1136/gut.2005.066100 (Epub ahead of print).